VANTAGE Archive — Page 1 of 2
-
August 17, 2022
Researchers discover how salt increases blood pressure
A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension. -
September 22, 2021
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant. -
March 11, 2021
‘Friendly’ bacteria may impact COVID severity
The U.S. Centers for Disease Control and Prevention (CDC) has awarded Vanderbilt University Medical Center a two-year, $3.7-million contract to determine genetic and bacterial factors that may increase the risk for severe illness and death from COVID-19. -
September 17, 2020
Grant from Google to support COVID gene expression study
Vanderbilt University Medical Center and the University of North Carolina (UNC) at Chapel Hill have been awarded $500,000 by Google’s philanthropy, Google.org, to study how COVID-19 alters gene expression in some people in ways that may be linked to their risk of severe illness and death. -
April 23, 2020
Collaboration key to rapid expansion of lab test capacity
The rapid ramping up of SARS-CoV-2 testing at VUMC reflects the dedication of the professionals who work in the Clinical Laboratory and also their collaboration with colleagues in research laboratories throughout VUMC. -
April 9, 2020
Study tracks genomics of lung tumor behavior
A study by Vanderbilt researchers has identified genomic alterations in early stage adenocarcinomas of the lung that may indicate whether the lesions develop into aggressive tumors. -
March 23, 2020
Researchers developing potential coronavirus antibody therapies
Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.